Global Investor Forum Contact

René Bernards

Founder, Qameleon Therapeutics & Professor of molecular carcinogenesis, Netherlands Cancer Institute

Session

14:15 - 15:25
From research to innovation

René Bernards’ laboratory at the Netherlands Cancer Institute uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. He founded Qameleon Therapeutics to repurpose abandoned and patent expired drugs for use in cancer. Qameleon aims to bring these drugs to patients at sustainable prices by working with investors who seek societal impact and generic drug makers.

Abstract

How much longer will we put up with $100,000 cancer drugs?
The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. Qameleon Therapeutics was founded to enable the development of truly transformative drugs at sustainable prices. To do this, abandoned drugs that lacked sufficient single agent activity and patent expired drugs will be repurposed for new indications through innovative genetic approaches. These drugs will be re-introduced into the clinic with financial support from investors seeking societal impact next to a reasonable return on investment. A first example of a new clinical use of an old drug will be presented.
Niels Chavannes
LUMC
Maarten van Dongen
LabForRent
Ingmar de Gooijer
myTomorrows
Mark van Houdenhoven
Sint Maartenskliniek

Henk van Houten
Philips

Arthur Lahr
Kiadis Pharma

Jos Malda
UMC Utrecht
Eveliene Manten-Horst
AYA Jongvolwassen & Kanker

Madelon Maurice
UMC Utrecht

Tom Miller
GreyBird Ventures
Edwin Moses
Ablynx
Kees Recourt
Mibiton Foundation

Maurits van Selms
ACTA

Marianne van der Steen
MERLN
Markwin Velders
Kite Pharma
Werner Verbiest
Janssen Diagnostics
Eline Vrijland-van Beest
NightBalance
Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Gold sponsor
Partner
Partner
Award sponsor
Your logo?
© 2018 Innovation for Health